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Abstract
High serum phosphorus levels have been linked with vascular calcification and greater
cardiovascular morbidity and mortality. We assessed whether serum phosphorus was associated
with the atrial fibrillation (AF) incidence in a large community-based cohort in the United States.
Our analysis included 14,675 participants (25% black, 45% men) free of AF at baseline (1987 to
1989) and with measurements of fasting serum phosphorus from the Atherosclerosis Risk In
Communities (ARIC) study. The incidence of AF was ascertained through the end of 2008 from
study visit electrocardiograms, hospitalizations, and death certificates. Cox proportional hazard
models were used to estimate the hazard ratios of AF by the serum phosphorus levels, adjusting
for potential confounders. During a median follow-up of 19.7 years, we identified 1,656 incident
AF cases. Greater serum phosphorus was associated with a greater AF risk: the hazard ratio of AF
with a 1-mg/dl increase in serum phosphorus was 1.13 (95% confidence interval 1.02 to 1.26). No
significant interaction was seen by race (p = 0.88) or gender (p = 0.51). The risk of AF was
increased in association with greater serum phosphorus in those with an estimated glomerular
filtration rate of ≥90 ml/min/1.72 m2 but not among those with an estimated glomerular filtration
rate of <90 ml/min/1.72 m2. The total corrected calcium levels were not related to AF risk;
however, greater levels of the calcium-phosphorus product were associated with greater AF risk.
In conclusion, in the present large population-based study, greater levels of serum phosphorus and
the related calcium-phosphorus product were associated with a greater incidence of AF.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated
with an increased risk of heart failure, stroke, and cardiovascular death.1 The established
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risk factors include age, white race, obesity, heart failure, coronary heart disease, left
ventricular hypertrophy, hypertension, certain lifestyle factors,2-4 and, recently, chronic
kidney disease (CKD).5 Increased phosphatemia because of impaired phosphorus excretion
with decreased kidney function could help explain the relation between AF and CKD if
phosphorus is an independent predictor of AF. Phosphorus is essential for numerous
biologic functions, including cellular signal transduction, mineral metabolism, and energy
exchange.6 Elevated phosphorus levels have been independently linked with calcification of
the aorta and coronary arteries, increased arterial stiffness, elevated left ventricular mass,
carotid atherosclerosis,7-13 and increased cardiovascular morbidity and mortality in subjects
with and without CKD.6,11,14-18 The present study estimated the association of serum
phosphorus levels with the incidence of AF in the Atherosclerosis Risk In Communities
(ARIC) study cohort. We also assessed whether the related serum calcium and calcium-
phosphorus product were associated with AF risk.
Methods
The ARIC study was a biracial, prospective cohort study of cardiovascular disease and
atherosclerosis risk factors.19 The participants at baseline (1987 to 1989) included 15,792
men and women aged 45 to 64 years, recruited from 4 communities in the United States
(Washington County, Maryland; northwest suburbs of Minneapolis, Minnesota; Jackson,
Mississippi; and Forsyth County, North Carolina). Additional details on the ARIC study can
be found in the online supplement. The institutional review board at each participating
center approved the present study, and all study participants provided written informed
consent.
The AF diagnoses were ascertained by 3 different sources in the ARIC study:
electrocardiograms performed at study visits, hospital discharge codes, and death
certificates. 2 Additional details of AF ascertainment can be found in the online supplement.
In the present analysis, the incidence date of AF was defined as the date for the first
electrocardiogram showing AF, the first hospital discharge coded as AF, or when AF was
listed as a cause of death, whichever occurred earlier.
Blood samples were collected at each visit after a fast of ≥8 hours and sent to the ARIC
Central Lipid Laboratory. The phosphorus, calcium, and creatinine levels were measured in
frozen serum samples, using methods based on ammonium molybdate, o-cresolphthalein
complexone, and modified kinetic Jaffe-picric acid, respectively.19,20 The coefficient of
variation was 2.4% for phosphorus, 1.9% for calcium, and 3.7% for creatinine. Detailed
procedures on baseline covariate measurements have been previously published19 and are
also available in the online supplement.
Of the 15,792 participants who attended visit 1 in the ARIC study, we excluded those who
were of a racial group other than white or black and nonwhites in the Minneapolis and
Washington County field centers (n = 103), those with prevalent AF at visit 1 (n = 37), low-
quality or missing electrocardiograms (n = 242), those missing phosphorus levels (n = 124),
those with nonfasting blood samples (n = 485), those missing covariates (n = 108), and those
with an estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m2 (n = 18). The final
sample included 14,675 participants (25% black, 45% men).
We estimated the association between the baseline serum phosphorus and calcium levels and
the incidence of AF using Cox proportional hazards models, with the interval to AF as the
main outcome variable. Initially, we explored the association between phosphorus and
calcium and AF risk using restricted cubic splines. Next, we categorized the serum
phosphorus and calcium levels and the calcium-phosphorus product by quintiles for the
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categorical analysis. p Values for trend were calculated across the quintile categories using
the quintile term. The follow-up period was defined as the interval elapsed between baseline
and the date of AF incidence, death, lost to follow-up, or December 31, 2008, whichever
came earlier. Models for the association of the phosphorus levels with AF risk were adjusted
for the baseline covariates, including age, gender, race, study site, education (less than
completed high school, high school diploma, at least some college), height (continuous),
smoking (never, former, current), alcohol drinking (never, former, current), body mass index
(continuous), diabetes (dichotomous), serum calcium (adjusted for albumin), systolic blood
pressure (continuous), diastolic blood pressure (continuous), use of antihypertensive
medications, eGFR (modeled as a spline), prevalent stroke, prevalent heart failure, and
prevalent coronary heart disease. An additional model was performed, adjusting for incident
heart failure and incident coronary heart disease as timevarying covariates. Models
considering calcium as the main exposure included the same covariates, except for adjusting
for phosphorus instead of calcium.
Because both excess phosphorus and an increased risk of AF have been independently
linked with CKD, we also examined the association of phosphorus and AF stratified by the
eGFR. Effect measure modification on the multiplicative scale was formally tested in the
multivariate model, including an interaction term between gender, race, and eGFR
categories and the phosphorus levels. The proportional hazards assumption was tested using
time interaction terms and inspection of log negative log survival curves. All statistical
analyses were performed with SAS, version 9.2 (SAS Institute, Cary, North Carolina).
Results
Selected characteristics for the ARIC participants by quintile of serum phosphorus level are
listed in Table 1. Women, blacks, current smokers, and those with prevalent heart failure
were more likely to have higher phosphorus levels. The mean ± SD of serum phosphorus
was 3.4 ± 0.5 mg/dl (interquartile range 3.1-3.7). The mean ± SD of calcium and the
calcium-phosphorus product was 9.9 ± 0.4 mg/dl and 33.9 ± 5.2, respectively. The
correlation coefficient between phosphorus and calcium was 0.16 and between phosphorus
and the calcium-phosphorus product was 0.96.
During a median follow-up of 19.7 years, we identified 1,656 incident AF cases. The
association between the serum phosphorus level and incident AF was examined using cubic
splines, showing a slight J-shaped or reversed L-shaped association (Figure 1), with a
nonsignificant phosphorus quadratic term (p = 0.32). The multivariate adjusted hazard ratio
of AF associated with 1-mg/dl higher serum phosphorus level was 1.13 (95% confidence
interval 1.02 to 1.26). Categorizing serum phosphorus in quintiles, a 20% greater risk of AF
was observed in the top quintiles compared to the lowest quintile, even after adjustment for
potential confounders (Table 2). The results were slightly attenuated in the uppermost
quintile with additional adjustment for time-varying heart failure and coronary heart disease.
The results did not differ with additional adjustment for incident hypertension, diuretic use,
vitamin D intake, or after adjustment for eGFR at visit 4 (data not shown).
After adjustment for potential confounders, the calcium levels were not associated with a
greater risk of AF, either as a continuous variable (hazard ratio 1.10, 95% confidence
interval 0.97 to 1.24, for a 1-mg/dl difference) or when categorized in quintiles (Table 2).
The association between the calcium-phosphorus product and AF risk was similar to that for
serum phosphorus alone (Table 2). The results were only slightly attenuated after additional
adjustment for incident heart failure and coronary heart disease and remained significant.
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No significant interaction was seen in the association between phosphorus and AF by race (p
= 0.88) or gender (p = 0.51). Associations between serum phosphorus and AF by gender are
reported in Table E1. Owing to the narrow interquartile range, we performed a sensitivity
analysis, excluding those with phosphorus levels lower than the 1st percentile and greater
than the 99th percentile to explore the influence of extreme values. The significance of the
association between phosphorus and AF did not change. The interaction between
phosphorus and AF by eGFR category was not significant (p = 0.18). There was an
increased risk of AF associated with higher serum phosphorus levels in those with an eGFR
≥90 ml/min/1.73 m2 but not among those with an eGFR <90 ml/min/1.73 m2 (Table 3). The
association of serum phosphorus with incident AF by kidney function using cubic splines
showed slight J-shaped associations in those with an eGFR >90 or <60 ml/min/1.73 m2, and
no association in those with an eGFR of 60 to 90 ml/min/1.73 m2 (Figure 2).
Discussion
In the present population-based prospective study, greater serum phosphorus levels and the
related calciumphosphorus product were associated with an increased risk of incident AF.
Phosphorus was associated with a greater AF risk in those with normal kidney function
(eGFR ≥90 ml/min/1.73 m2); thus, the effect of phosphorus is not driven solely by poor
kidney function. This association was independent of lifestyle factors, clinical factors, and
cardiovascular disease and was similar in terms of gender and race. In our analysis, the
association between phosphorus and AF was similar in direction and magnitude to the
associations seen between phosphorus levels and increased risks of cardiovascular disease
and mortality in patients with CKD or coronary disease and in the general
population.6,14,16-18
Several potential mechanisms might explain the increased risk of AF with greater
phosphorus levels. First, excess phosphorus levels have been linked to calcification of the
aorta and coronary arteries,7,8 thereby increasing vascular calcification and smooth muscle
proliferation and directly promoting vascular injury, which could lead to greater AF risk.
Second, high phosphorus levels are known to inhibit 1,25-dihydroxyvitamin D synthesis,21
and it has been hypothesized that lower 1,25-dihydroxyvitamin D levels also increase
coronary calcification and decrease cardiac contractility,22,23 possibly leading to increased
an risk of AF. Third, excess phosphorus has been associated with secondary
hyperparathyroidism, which involves increased circulating levels of parathyroid hormone
(PTH). High PTH levels might be proinflammatory, leading to an increased risk of AF. In a
recent cross-sectional study, PTH was elevated in patients with AF compared to controls in
sinus rhythm.24 However, the associations of phosphorus with death or cardiovascular
outcomes were not affected after adjustments for PTH14 or the inflammatory marker, high-
sensitivity C-reactive protein, in other populations.17 Other mechanisms that could mediate
the association between serum phosphorus and AF risk include an increased left ventricular
mass and greater risk of heart failure in those with higher phosphorus levels.11 Finally,
fibroblast growth factor 23, a phosphate-regulating hormone that reflects serum phosphorus
levels, has been associated with left ventricular dysfunction and the prevalence of AF in
patients undergoing coronary angiography.25
No clear association was found between the calcium level and AF risk. Therefore, the
observed association between the calcium-phosphorus product and AF was probably
attributable to serum phosphorus. These results are consistent with those of previous studies
of other cardiovascular outcomes.14,15,17,18
In the present analysis, we found that serum phosphorus was associated with greater AF risk
only among those with normal kidney function, as measured by the eGFR, but not among
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those with reduced eGFR, although the reduced eGFR groups had fewer outcomes and low
power. The phosphorus levels correlated with kidney function, and because it does not
appear that elevated phosphorus is on the pathway between CKD and AF, we can only
speculate about the reasons for this potential interaction, given that in ARIC, participants
with a lower eGFR had a greater risk of AF.5 If other mechanisms different from serum
phosphorus are associated with increased AF risk in those with lower eGFR, higher
phosphorus levels might not result in additional risk in this group. Our observation could be
a chance finding, and future studies should try to replicate it.
Our study had major strengths, including a large number of incident AF cases, which
provided adequate power to identify moderate associations, the community-based biracial
sample, which increases the generalizability of our results, and the availability of an
extensive list of measured covariates, which allowed adequate adjustment for most
confounders. Still, some study limitations should be noted. Asymptomatic AF and AF
managed exclusively in an outpatient facility could not be identified, because the large
majority of our incident AF cases were ascertained from the hospitalization discharge
records. We have found, however, adequate validity of these codes for the identification of
AF events.2 The strength of the association between phosphorus and AF was modest, and
residual confounding, if present, could explain the association. However, we adjusted for
most known risk factors that were measured well in the ARIC study, making this less likely.
Misclassification of the exposure could also occur because of within-person variability in
serum phosphorus levels. Finally, the ARIC study did not contain information on thyroid
profiles or PTH, which could potentially be confounders in our study.
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Association between serum phosphorus levels, modeled as restricted cubic spline, and AF
(ARIC 1987 to 2008). Model adjusted for age, gender, and race. Black line represents
hazard ratio; gray shaded area, 95% confidence interval.
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Association between serum phosphorus levels, modeled as restricted cubic spline, and AF
and stratified by eGFR (≥90, 60 to 90, <60 ml/min/1.73 m2), ARIC 1987 to 2008. Models
adjusted for age, gender, and race. Black line represents hazard ratio; gray shaded area, 95%
confidence interval. (A) eGFR ≥90 ml/min/1.73 m2 (n = 10,149; AF events = 1,022), (B)
eGFR 60 to 90 ml/min/1.73 m2 (n = 4,292; AF events = 587), (C) eGFR <60 ml/min/1.73
m2 (n = 234; AF events = 47).
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